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673Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and
Patient Outcomes)Objectives The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to
compare the efﬁcacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and
after PCI in the setting of acute coronary syndrome.
Background Greater platelet inhibition has been associated with improved angiographic outcomes before
and after percutaneous coronary intervention (PCI). Therefore, it was hypothesized that treatment with
ticagrelor, which achieves more rapid, higher, and more consistent platelet inhibition, would be associated
with improved angiographic outcomes when compared with those of clopidogrel treatment.
Methods The angiographic cohort consists of 2,616 patients drawn from the 18,624-patient PLATO trial.
Clopidogrel naïve or pre-treated patients were randomized to 180 mg of ticagrelor or 300 mg of
clopidogrel (75 mg for clopidogrel pre-treated patients). PCI patients were administered, as per
treatment group: 1) an additional 90 mg of ticagrelor if >24 h following the initial loading dose; or 2) an
optional further 300 mg of clopidogrel or placebo (total 600 mg) prior to PCI. The substudy primary
endpoint was the incidence of post-PCI TIMI (Thrombolysis In Myocardial Infarction) myocardial
perfusion grade 3 (TMPG 3) among patients who received a study drug prior to PCI.
Results In total, 21.3% of patients were pretreated with clopidogrel prior to randomization. There was
a short time interval between randomization and PCI (median: 0.68 [interquartile range (IQR): 0.30 to
2.21] h) among all patients. Post-PCI TMPG 3 was similar between the ticagrelor and clopidogrel groups
(47.1% vs. 46.9%; p ¼ 0.96). Likewise, the following pre-PCI outcomes were similar in the ticagrelor and
clopidogrel groups, respectively: TMPG 3 (30.5% vs. 31.2%), TIMI ﬂow grade 3 (37.1% vs. 39.3%),
corrected TIMI frame count (median: 100 vs. 71 frames), TIMI thrombus grade 0 (24.1% vs. 27.6%),
minimum lumen diameter (median: 0.3 [IQR: 0.0 to 0.6] vs. 0.3 [IQR: 0.0 to 0.6] mm) and percentage of
diameter stenosis (median: 89 [IQR: 78 to 100] vs. 89 [IQR: 77 to 100]).
Conclusions Neither coronary ﬂow nor myocardial perfusion, evaluated on coronary angiograms
performed before or following PCI procedures within a few hours after the start of oral antiplatelet
treatment in the setting of acute coronary syndromes, demonstrated a difference with ticagrelor versus
clopidogrel. (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary
Syndrome [PLATO]; NCT00391872) (J Am Coll Cardiol Intv 2013;6:671–83) ª 2013 by the American
College of Cardiology FoundationIn the PLATO (Platelet Inhibition and Patient Outcomes)
trial (1), long-term treatment with ticagrelor, compared with
clopidogrel, results in a signiﬁcant reduction in the composite
endpoint of death from vascular causes, myocardial infarction
(MI), or stroke among patients presenting with acute coro-
nary syndromes (ACS). Ticagrelor inhibits platelet activation
and aggregation by selectively and reversibly blocking plate-
let P2Y12 receptors (2). The likely mechanism of clinical
beneﬁt is thought to be more potent and more predictableSee page 684P2Y12 inhibition with ticagrelor compared with clopidogrel
(3–5). Greater platelet inhibition with glycoprotein IIb/IIIainhibitors has been associated with improved angiographic
outcomes before and after percutaneous coronary interven-
tion (PCI). In particular, greater platelet inhibition has been
associated with improved myocardial perfusion before and
after PCI, and improvements in myocardial perfusion have in
turn been associated with improved clinical outcomes (6–9).
Therefore, it could be hypothesized that the greater platelet
inhibition associated with ticagrelor may in turn lead to
improved angiographic outcomes that may be associated with
the superior clinical outcomes associated with ticagrelor
administration. Ticagrelor is also known to inhibit cell uptake
of adenosine, and it could also be hypothesized that, by
inhibiting this process, ticagrelor might increase adenosine’s
concentration in themyocardium and thereby further enhance
the positive and beneﬁcial effects of adenosine in the
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674microvasculature, such as hyperemia and vasodilation, and
minimize reperfusion injury in the myocardium.
The goal of the PLATO angiographic substudy was to
compare the efﬁcacy of ticagrelor versus clopidogrel with
respect to angiographic outcomes before and after PCI.
Methods
Main study design. The PLATO trial was a multicenter,
randomized, double-blind study (10). The primary results
and the details of the design are published elsewhere (10).
The angiographic substudy was designed in collaboration
with the academic chairs and members of the steering
committee. The angiographic data were collected by the
PERFUSE (Pharmacologic/Percutaneous Endoluminal Re-
vascularization For Unstable Syndromes and its Evaluation)Abbreviations
and Acronyms
ACS = acute coronary
syndromes
CTFC = corrected TIMI frame
count
IQR = interquartile range
MI = myocardial infarction
NSTE = non–ST-segment
elevation
PCI = percutaneous coronary
intervention
PD = pharmacodynamic
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial Infarction
TMPG = TIMI myocardial
perfusion gradestudy group, an academic
research organization. The
sponsor coordinated the data
management. The statistical
analysis of the angiographic
substudy was performed by Duke
Clinical Research Institute in
collaboration with the investiga-
tors. National and local regula-
tory and ethics committees
approved the PLATO trial. All
subjects provided written
informed consent.
Study patients. Inclusion criteria
for enrollment included hospi-
talization for an ACS, with or
without ST-segment elevation,
with an onset of symptoms
during the previous 24 h. For
patients who had an ACS
without ST-segment elevation
(non–ST-segment elevation
[NTSE]), or NTSE-ACS, atFigure 1. PLATO Angiography Substudy Flow Chart
PCI ¼ percutaneous coronary intervention; PLATO ¼ Platelet Inhibition and
Patient Outcomes study.least 2 of the following 3 criteria had to be met: 1) ST-
segment changes on electrocardiography, indicating is-
chemia; 2) a positive test of a biomarker, indicating myo-
cardial necrosis; or 3) 1 of several risk factors (age 60 years;
previous MI or coronary artery bypass graft; coronary artery
disease with stenosis of 50% in at least 2 vessels; previous
ischemic stroke, transient ischemic attack, carotid stenosis of
at least 50%, or cerebral revascularization; diabetes mellitus;
peripheral arterial disease; or chronic renal dysfunction,
deﬁned as a creatinine clearance of <60 ml/min per 1.73 m2
of body surface area). For patients who had an ACS with
ST-segment elevation, the following 2 inclusion criteria
had to be met: 1) either persistent ST-segment elevation
of at least 0.1 mV in at least 2 contiguous leads or a new
left bundle branch block; and 2) the intention to performprimary PCI. Key major exclusion criteria were any con-
traindication to the use of clopidogrel, ﬁbrinolytic therapy
within 24 h before randomization, a need for oral anti-
coagulation therapy, an increased risk of bradycardia, and
concomitant therapy with a strong cytochrome P-450 3A
inhibitor or inducer. All sites were invited to participate in
the angiographic substudy.
Study treatment. Patients were randomly assigned to receive
either ticagrelor or clopidogrel, administered in a double-blind,
double-dummy fashion. Patients were clopidogrel-naïve or
pre-treated. Ticagrelor was administered as a loading dose of
180 mg followed by a maintenance dose of 90 mg twice daily.
Patients in the clopidogrel group who had not received an
open-label loading dose, or who had not been taking clopi-
dogrel for at least 5 days before randomization, received a 300-
mg loading dose of clopidogrel followed by a dose of 75 mg
daily. Other patients in the clopidogrel group continued to
receive amaintenance dose of 75mg daily. Patients undergoing
PCI following randomization received, in a blinded fashion, an
additional dose of their study drug at the time of PCI: 300 mg
of clopidogrel, at the investigator’s discretion; or 90 mg of
ticagrelor for patients who were undergoing PCI more than
24 h following randomization. All patients received ace-
tylsalicylic acid (aspirin) at a maintenance dose of 75 to
100mg daily unless they could not tolerate the drug. For those
who had not previously been treated with aspirin, up to 325
mgwas the preferred loading dose; 325mgwas also permitted
as the daily dose for 6 months following stent implantation.
Angiographic endpoints. Angiography was performed
according to local practice patterns. The TIMI (Throm-
bolysis In Myocardial Infarction) myocardial perfusion grade
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675(TMPG) (11,12), corrected TIMI frame count (CTFC) (13),
TIMI ﬂow grade (14), angiographic perfusion score (15),
TIMI thrombus grade (16), minimum lumen diameter,
and percentage of diameter stenosis were assessed at the
PERFUSE angiographic core laboratory and were blinded to
treatment assignment.
The primary efﬁcacy endpoint was the incidence of normal
TMPG (TMPG 3) following PCI among all patients who
were treated with the study drug prior to PCI. The following
secondary endpoints were also assessed: the CTFC following
PCI in all patients who were treated with the study drug
prior to PCI. Among patients who were treated with anTable 1. Baseline Characteristics in PLATO Angiographic S
Overal
N ¼ 2,06
Age, yrs 61.0  10
Age, 75 yrs 239 (11
Sex
Male 1,511 (73
Female 557 (26
Intended treatment approach at randomization
Invasive 1,971 (95
Medically managed 97 (4.7
History
Myocardial infarction 333 (16
Congestive heart failure 57 (2.8
PCI 253 (12
CABG 97 (4.7
TIA 35 (1.7
Nonhemorrhagic stroke 45 (2.2
Peripheral arterial disease 112 (5.4
Chronic renal disease 60 (2.9
STEMI: persistent ST-segment elevation or LBBB 1,175 (56
Final diagnosis
STEMI 1,154 (55
Unstable angina 180 (8.7
NSTEMI 715 (34
Other 19 (0.9
Troponin I
Positive 1,814 (88
Negative 230 (11
CV risk factors
Habitual smoker 891 (43
Hypertension 1,262 (61
Dyslipidemia 868 (42
Diabetes mellitus 412 (19
Clopidogrel pre-randomization*
600 mg 440 (21
Clopidogrel loading dose, 600 mgy 778 (37
Values are mean  SD or n (%). *Open-label clopidogrel received on the d
open-label clopidogrel pre-randomization plus IP clopidogrel/placebo dose
CABG ¼ coronary artery bypass graft; CV ¼ cardiovascular; IP
NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ perc
Patient Outcomes study; STEMI ¼ ST-segment elevation myocardial infarctactive drug prior to cardiac catheterization, the following pre-
PCI endpoints were secondary endpoints: pre-PCI TMPG,
CTFC, TIMI thrombus grade, TIMI ﬂow grade, minimum
lumen diameter, and percentage of diameter stenosis.
Statistical analysis. Based on a post-PCI TMPG 3 rate of
52% in the clopidogrel arm in NSTE-ACS patients and
48% in the clopidogrel arm in ST-segment elevation
myocardial infarction (STEMI) patients, 1,628 patients
(814 per arm) would be required to detect a 20% difference
with ticagrelor given 80% power (previous experience,
unpublished data). To allow for nonevaluable angiograms
and dropouts, 1,800 patients were planned to be enrolled inubstudy
l
8
Ticagrelor
n ¼ 1,053
Clopidogrel
n ¼ 1,015 p Value
.9 61.0  10.9 61.1  10.8 0.9988
.6) 121 (11.5) 118 (11.6) 0.9452
.1) 772 (73.3) 739 (72.8) 0.8044
.9) 281 (26.7) 276 (27.2)
.3) 1,005 (95.4) 966 (95.2) 0.8354
) 48 (4.6) 49 (4.8)
.1) 181 (17.2) 152 (15.0) 0.1880
) 36 (3.4) 21 (2.1) 0.0799
.2) 132 (12.5) 121 (11.9) 0.6875
) 51 (4.8) 46 (4.5) 0.7560
) 18 (1.7) 17 (1.7) 1.0000
) 22 (2.1) 23 (2.3) 0.8804
) 61 (5.8) 51 (5.0) 0.4965
) 30 (2.9) 30 (3.0) 0.8966
.8) 600 (57.0) 575 (56.7) 0.8941
.8) 584 (55.5) 570 (56.2) 0.9356
) 89 (8.5) 91 (9.0)
.6) 370 (35.1) 345 (34.0)
) 10 (1.0) 9 (0.9)
.8) 918 (88.5) 896 (89.0) 0.7796
.2) 119 (11.5) 111 (11.0)
.1) 444 (42.2) 447 (44.0) 0.3989
.0) 664 (63.1) 598 (58.9) 0.0582
.0) 442 (42.0) 426 (42.0) 1.0000
.9) 210 (19.9) 202 (19.9) 1.0000
.3) 236 (22.4) 204 (20.1) 0.2164
.6) 397 (37.7) 381 (37.5) 0.9638
ay of randomization or the day before randomization. yComputed as
(within 24 h of the ﬁrst dose of IP).
¼ investigational product; LBBB ¼ left bundle branch block;
utaneous coronary intervention; PLATO ¼ Platelet Inhibition and
ion; TIA ¼ transient ischemic attack.
Table 2. Timing of Procedures Following Randomization
Procedure Timing Overall Ticagrelor Clopidogrel p Value
Angiography
During index hospitalization 2,047 (98.9) 1,040 (98.8) 1,007 (99.2) 0.3826
Time to angiography, min 20 (1–101) 20 (0–90) 21 (1–112) 0.2909
In STEMI patients, min 9 (–4–27) 10 (–4–30) 9 (–3–24) 0.7446
In NSTE-ACS patients, min 92 (21–966) 79 (17–744) 112 (26–1,147) 0.0563
PCI
During index hospitalization 2,036 (98.5) 1,037 (98.5) 999 (98.4) 1.0000
Time to PCI, h 0.68 (0.30–2.21) 0.68 (0.28–1.97) 0.68 (0.30–2.42) 0.3736
In STEMI patients, h 0.42 (0.23–0.83) 0.40 (0.23–0.85) 0.42 (0.23–0.80) 0.8070
In NSTE-ACS patients, h 2.12 (0.68–19.33) 1.77 (0.63–17.83) 2.42 (0.80–21.27) 0.0834
CABG
During study 89 (4.3) 45 (4.3) 44 (4.3) 1.0000
Time to CABG, days 94 (50–192) 85 (56–208) 96 (46–167) 0.7897
In STEMI patients, days 98 (60–209) 98 (72–202) 100 (46–216) 0.9137
In NSTE-ACS patients, days 84 (38–137) 84 (38–219) 82 (45–111) 0.5934
Values are n (%) or median (IQR).
IQR ¼ interquartile range; NSTE-ACS ¼ Non–ST-segment elevation acute coronary syndromes.
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676this substudy. It was planned to recruit an equal number
of patients with STEMI (n ¼ 900) and NSTE-ACS
(n ¼ 900) into the substudy.
Baseline characteristics were compared between the 2
treatment groups using Fisher exact test for categorical
variables or the Wilcoxon rank-sum test for continuousTable 3. Primary Endpoint: Post-PCI TMPG
All patients
Normal ¼ TMPG 3
STEMI patients*
Normal ¼ TMPG 3
NSTE-ACS patients
Normal ¼ TMPG 3
Primary endpoint: post-PCI TMPG clopidogrel pre-randomizationy
In patients with clopidogrel pre-randomization 600 mg/day
Normal
Abnormal
In patients with clopidogrel pre-randomization <600 mg/day
Normal
Abnormal
Primary endpoint: post-PCI TMPG clopidogrel loading dosez
In patients with clopidogrel pre-randomization 600 mg/day
Normal
Abnormal
In patients with clopidogrel pre-randomization <600 mg/day
Normal
Abnormal
Values are n/N (%) or n (%). The p value for the treatment by type of ACS in
or new LBBB. yClopidogrel pre-randomization deﬁned as open-label clo
randomization. The p value for the treatment by clopidogrel interaction is 0.
clopidogrel/placebo dose (within 24 h of the ﬁrst dose of IP). The p value
TMPG ¼ TIMI [Thrombolysis In Myocardial Infarction] myocardial perfusvariables. The interaction between randomized treatment
and presenting syndrome for the primary angiographic
endpoint was tested using a logistic regression model. The
primary endpoint was also analyzed stratifying by presenting
syndrome: either NSTE-ACS or STEMI. A p value of
<0.05 was considered statistically signiﬁcant. All analysesOverall Ticagrelor Clopidogrel p Value
779/1,657 (47.0) 396/841 (47.1) 383/816 (46.9) 0.9608
412/989 (41.7) 213/502 (42.4) 199/487 (40.9) 0.6517
367/668 (54.9) 183/339 (54.0) 184/329 (55.9) 0.6411
n ¼ 361 n ¼ 190 n ¼ 171
160 (44.3) 79 (41.6) 81 (47.4) 0.2896
201 (55.7) 111 (58.4) 90 (52.6)
n ¼ 1,296 n ¼ 651 n ¼ 645
619 (47.8) 317 (48.7) 302 (46.8) 0.5051
677 (52.2) 334 (51.3) 343 (53.2)
n ¼ 645 n ¼ 331 n ¼ 314
293 (45.4) 144 (43.5) 149 (47.4) 0.3426
352 (54.6) 187 (56.5) 165 (52.6)
n ¼ 1,012 n ¼ 510 n ¼ 502
486 (48.0) 252 (49.4) 234 (46.6) 0.3791
526 (52.0) 258 (50.6) 268 (53.4)
teraction is 0.4790. *STEMI deﬁned as persistent ST-segment elevation
pidogrel received on the day of randomization or the day before
1964. zComputed as open-label clopidogrel pre-randomization plus IP
for the treatment by clopidogrel interaction is 0.1796.
ion grade; other abbreviations as in Tables 1 and 2.
Table 4. Primary Endpoint: Post-PCI TMPG by Aspirin Dose
Overall
n ¼ 1,657
Ticagrelor
n ¼ 841
Clopidogrel
n ¼ 816 p Value
Aspirin dose on
randomization day
<100 mg
Normal 168 (54.9) 82 (54.3) 86 (55.5) 0.8358
Abnormal 138 (45.1) 69 (45.7) 69 (44.5)
100–299 mg
Normal 180 (48.8) 93 (48.9) 87 (48.6) 0.9473
Abnormal 189 (51.2) 97 (51.1) 92 (51.4)
300 mg
Normal 431 (43.9) 221 (44.2) 210 (43.6) 0.8420
Abnormal 551 (56.1) 279 (55.8) 272 (56.4)
Aspirin dose on day 1
after randomization
<100 mg
Normal 364 (46.8) 191 (47.4) 173 (46.3) 0.7508
Abnormal 413 (53.2) 212 (52.6) 201 (53.7)
100–299 mg
Normal 345 (46.0) 171 (45.7) 174 (46.3) 0.8789
Abnormal 405 (54.0) 203 (54.3) 202 (53.7)
300 mg
Normal 69 (53.5) 33 (52.4) 36 (54.6) 0.8054
Abnormal 60 (46.5) 30 (47.6) 30 (45.4)
Values are n (%).
Abbreviations as in Tables 1 and 3.
Table 5. Primary Endpoint: Post-PCI TMPG by Glycoprotein IIb/IIIa
Inhibitors on Randomization Day
Overall
n ¼ 1,657
Ticagrelor
n ¼ 841
Clopidogrel
n ¼ 816 p Value
Glycoprotein IIb/IIIa
inhibitors ¼ “no”
Normal 483 (46.8) 245 (46.1) 238 (47.6) 0.6386
Abnormal 548 (53.2) 286 (53.9) 262 (52.4)
Glycoprotein IIb/IIIa
inhibitors ¼ “yes”
Normal 296 (47.3) 151 (48.7) 145 (45.9) 0.4793
Abnormal 330 (52.7) 159 (51.3) 171 (54.1)
Values are n (%). The p value for interaction between glycoprotein IIb/IIIa inhibitors and
randomized treatment is 0.3971.
Abbreviations as in Tables 1 and 3.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3 Kunadian et al.
J U L Y 2 0 1 3 : 6 7 1 – 8 3 PLATO Angiographic Substudy
677were carried out using SAS software (version 9.2, SAS
Institute Inc., Cary, North Carolina) statistical software.
Results
In the main PLATO trial, there were 18,624 patients with
ACS, recruited from 862 centers in 43 countries, who were
randomized to either ticagrelor or clopidogrel. The angio-
graphic substudy consisted of 2,616 patients (Fig. 1), of
whom 2,068 received the study drug (ticagrelor: n ¼ 1,053,
and clopidogrel: n ¼ 1,015) prior to PCI and are included in
the present analysis. Of these, 1,657 PCI patients had
angiographic images that were suitable for the analysis of the
primary endpoint (TMPG). There were 27 countries and
161 sites that contributed to the PLATO angiographic
substudy.
Baseline characteristics. The baseline characteristics of the
angiographic substudy patients are displayed in Table 1. The
mean age was 61  10.9 years among all patients included in
the angiographic substudy. In total, 95.3% of patients were
identiﬁed by the investigator as intended for invasive man-
agement at the time of randomization, and the remaining
patients were initially intended for medical management. In
accordance with the planning, approximately one-half of the
angiography substudy cohort consisted of patients with
a ﬁnal diagnosis of STEMI (55.8%) and one-half with a ﬁnaldiagnosis of NSTE-ACS: that is, non-STEMI (34.6%) and
unstable angina (8.7%). There were no signiﬁcant differences
in the baseline variables between the ticagrelor and clopi-
dogrel groups. In total, 21.3% of patients received clopidogrel
prior to randomization with no difference between the 2
study groups (22.4% vs. 20.1% in the ticagrelor and clopi-
dogrel groups, respectively; p ¼ 0.2164). The timing of
procedures following the administration of the study drug is
displayed in Table 2. There was a short time interval
between randomization and PCI in the PLATO angio-
graphic substudy cohort (median: 0.68 [interquartile range
(IQR): 0.30 to 2.21] h), with no difference between the
2 study groups (p ¼ 0.3736).
Angiographic primary endpoint. There was no signiﬁcant
difference in the occurrence of post-PCI TMPG 3 between
the ticagrelor and clopidogrel treatment groups (396
[47.1%] vs. 383 [46.9%]; p ¼ 0.96) in the overall population
of the angiographic substudy. Likewise, there were no
differences in the occurrence of post-PCI TMPG 3
between the ticagrelor and clopidogrel treatment groups
among STEMI patients (213 [42.4%] vs. 199 [40.9%];
p ¼ 0.65) and NSTE-ACS patients (183 [54%] vs. 184
[55.9%]; p ¼ 0.64), respectively (Table 3).
Among the patients with available primary endpoint, 388
(23%) patients (311 NSTE-ACS and 77 STEMI) had the
angiography 1 h or later following the administration of
the ﬁrst dose of the study drug. Of the 311 NSTE-ACS
patients, 154 were randomized to ticagrelor and 157 to
clopidogrel. TMPG 3 was observed in 79 of 154 patients
(51.3%) in ticagrelor versus 84 of 157 patients (53.5%) in
clopidogrel groups (p ¼ 0.73).
Among the patients with available primary endpoint, 305
(18%) patients (259 NSTE-ACS and 46 STEMI) had the
angiography 2 h or later following the administration of the
ﬁrst dose of the study drug. Of the 259 NSTE-ACS
patients, 133 were randomized to ticagrelor and 126 to
clopidogrel. TMPG 3 was observed in 65 of 133 (48.9%)
Table 6. Secondary Post-PCI Angiographic Variables
n Overall Ticagrelor Clopidogrel p Value
Corrected TIMI frame count 1,605 21 (15–31) 22 (16–32) 21 (15–31) 0.2836
Minimum culprit artery, mm 1,938 2.4 (2.1–2.8) 2.4 (2.1–2.8) 2.4 (2.1–2.8) 0.1955
Average culprit artery, mm 1,935 2.6 (2.3–3.0) 2.6 (2.3–3.0) 2.6 (2.3–2.9) 0.3171
Stenosis of culprit artery, % 1,958 6 (–1–14) 5 (–1–13) 6 (–1–14) 0.3147
Lesion length, mm 1,915 2.7 (2.4–3.1) 2.7 (2.4–3.1) 2.7 (2.4–3.1) 0.1656
TIMI ﬂow grade 1,950
0 ¼ no perfusion 27 (1.4) 11 (1.1) 16 (1.7) 0.5527
1 ¼ penetration without perfusion 34 (1.7) 19 (1.9) 15 (1.6)
2 ¼ partial perfusion 195 (10.0) 94 (9.5) 101 (10.5)
3 ¼ complete perfusion 1,694 (86.9) 869 (87.5) 825 (86.2)
PCI success 1,970
Failure 63 (3.2) 31 (3.1) 32 (3.3) 0.8775
Partial, >50% stenosis 169 (8.6) 89 (8.8) 80 (8.3)
Complete, <50% stenosis 1,738 (88.2) 886 (88.1) 852 (88.4)
Pulsatile ﬂow, yes 1,922 350 (18.2) 185 (18.8) 165 (17.6) 0.5155
Thrombus grade 1,977
0 ¼ no thrombus 1,886 (95.4) 967 (95.5) 919 (95.2) 0.6262
1 ¼ hazy-possible thrombus present 19 (1.0) 13 (1.3) 6 (0.6)
2 ¼ thrombus present-small size 8 (0.4) 3 (0.3) 5 (0.5)
3 ¼ thrombus present-moderate size 15 (0.8) 8 (0.8) 7 (0.7)
4 ¼ thrombus present-large size 12 (0.6) 5 (0.5) 7 (0.7)
5 ¼ recent total occlusion 33 (1.7) 14 (1.4) 19 (2.0)
6 ¼ chronic total occlusion 4 (0.2) 2 (0.2) 2 (0.2)
Angiographic perfusion score 1,516
0–3 123 (8.1) 58 (7.5) 65 (8.7) 0.0488
4–6 609 (40.2) 335 (43.5) 274 (36.7)
7–9 304 (20.0) 141 (18.3) 163 (21.9)
10–12 480 (31.7) 236 (30.7) 244 (32.7)
Values are median (IQR) and n (%).
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 and 2.
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678patients in ticagrelor versus 61 of 126 (48.4%) patients in
clopidogrel groups (p ¼ 1.0).
In the subgroup of patients with pre-PCI TMPG 0 or
1, 534 were randomized to ticagrelor and 502 to clopidogrel.
Primary endpoint was observed in 186 (34.8%) of ticagrelor
patients and 158 (31.5%) of clopidogrel patients (p ¼ 0.26).
There was no difference in the primary endpoint of
post-PCI TMPG 3 among STEMI (ticagrelor: 133 of
380 [35%] vs. clopidogrel: 108 of 3,350 [30.9%]; p ¼ 0.24)
and NSTE-ACS (ticagrelor: 53 of 154 [34.4%] vs. clopi-
dogrel: 50 of 152 [32.9%]; p ¼ 0.81) patients between the
2 groups.
Further, there was no difference in the post-PCI TMPG
between ticagrelor and clopidogrel groups among patients
who were administered clopidogrel pre-randomization,
which is deﬁned as open-label clopidogrel received on the
day of randomization or the day before randomization, and
those who were administered open-label clopidogrel pre-
randomization plus investigational product clopidogrel/
placebo dose (within 24 h of the ﬁrst dose of investigational
product) (Table 3). There was no difference in the post-PCITMPG between the 2 treatment groups among patients
who received different doses of aspirin and the results are
displayed in Table 4. There was also no difference in the
post-PCI TMPG between the 2 treatment groups among
patients who did and did not receive glycoprotein IIb/IIIa
inhibitors on the day of randomization and the results are
displayed in Table 5.
Angiographic secondary endpoints post-PCI. Complete pro-
cedural success (<50% stenosis and TIMI ﬂow grade 3)
occurred in 886 (88.1%) patients in the ticagrelor group and
852 (88.4%) in the clopidogrel group (Table 6). There was
no signiﬁcant difference in CTFC (median: 22 [IQR: 16 to
32] vs. 21 [IQR: 15 to 31]; p ¼ 0.28) following PCI among
patients who received either ticagrelor or clopidogrel prior to
PCI. The incidence of normal epicardial ﬂow (TIMI ﬂow
grade 3) did not differ between the ticagrelor and clopidogrel
groups (869 [87.5%] vs. 825 [86.2%]) following PCI. No
differences were identiﬁed in other angiographic parameters
including minimum lumen diameter, average culprit artery
diameter, percentage stenosis of culprit artery, or lesion
length following PCI between the 2 treatment groups.
Table 7. Secondary Pre-PCI Angiographic Variables
n Overall Ticagrelor Clopidogrel p Value
Disease extent 2,003
1 vessel 589 (29.4) 302 (29.5) 287 (29.3) 0.9933
2 vessels 631 (31.5) 323 (31.5) 308 (31.5)
3 vessels 783 (39.1) 399 (39.0) 384 (39.2)
Culprit lesion location 2,068
LAD 790 (38.2) 413 (39.2) 377 (37.1) 0.7157
LCX 462 (22.3) 236 (22.4) 226 (22.3)
RCA 704 (34.0) 348 (33.1) 356 (35.1)
LM 18 (0.9) 11 (1.0) 7 (0.7)
Diagonal 53 (2.6) 24 (2.3) 29 (2.9)
SVG 40 (1.9) 21 (2.0) 19 (1.9)
Other 1 (<0.1) 0 (0.0) 1 (0.1)
Culprit artery dominance 2,044
Left 154 (7.5) 80 (7.7) 74 (7.4) 0.2092
Right 1,795 (87.8) 922 (88.5) 873 (87.1)
Codominant 95 (4.7) 40 (3.8) 55 (5.5)
TIMI myocardial perfusion grade 1,846
3 ¼ normal 569 (30.8) 284 (30.5) 285 (31.2) 0.7624
0–2 ¼ abnormal 1,277 (69.2) 648 (69.5) 629 (68.8)
TIMI ﬂow grade 2,040
0 ¼ no perfusion 775 (38.0) 413 (39.8) 362 (36.1) 0.3866
1 ¼ penetration without perfusion 150 (7.4) 74 (7.1) 76 (7.6)
2 ¼ partial perfusion 336 (16.5) 165 (15.9) 171 (17.0)
3 ¼ complete perfusion 779 (38.2) 385 (37.1) 394 (39.3)
Corrected TIMI frame count 1,918 86 (30–100) 100 (30–100) 71 (29–100) 0.1544
Minimum culprit artery, mm 2,038 0.3 (0.0–0.6) 0.3 (0.0–0.6) 0.3 (0.0–0.6) 0.6225
Average culprit artery, mm 2,015 2.6 (2.1–3.0) 2.6 (2.2–3.1) 2.5 (2.1–3.0) 0.0599
Stenosis of culprit artery, % 2,048 89 (77–100) 89 (78–100) 89 (77–100) 0.4194
Lesion length, mm 1,199 8.4 (6.0–11.9) 8.6 (6.1–12.6) 8.3 (5.9–11.5) 0.1643
Values are n (%) and median (IQR).
LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; LM ¼ left main stem; RCA ¼ right coronary artery; SVG ¼ saphenous
vein graft; other abbreviations as in Tables 1 and 6.
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679Angiographic secondary endpoints pre-PCI. The pre-PCI
angiographic variables are displayed in Tables 7 and 8. There
was no signiﬁcant difference in CTFC (median: 100 [IQR:
30 to 100] vs. 71 [IQR: 29 to 100]; p ¼ 0.15), TMPG 3
(284 [30.5%] vs. 285 [31.2%]), TIMI ﬂow grade 3 (385
[37.1%] vs. 394 [39.3%]), and TIMI thrombus grade 0 (252
[24.1%] vs. 279 [27.6%]) measured prior to PCI between
the ticagrelor and clopidogrel groups. There were no dif-
ferences in other baseline angiographic parameters including
disease extent, culprit lesion location, culprit artery domi-
nance, minimum culprit artery diameter, average culprit
artery diameter, percentage stenosis of culprit artery, lesion
length, and presence of collaterals measured prior to PCI
between the ticagrelor and clopidogrel groups (Tables 7
and 8). The ticagrelor group, compared with the clopidogrel
group, consisted of more patients with diffuse disease (7.2%
vs. 3.7%; p ¼ 0.0077).During PCI, no differences were identiﬁed in the oc-
currence of dissection (none: 992 [98.4%] vs. 941 [97.4%]),
perforation (localized: 3 [0.3%] vs. 1 [0.1%]), loss of side
branch (63 [6.3%] vs. 44 [4.6%]; p ¼ 0.11), distal emboli-
zation (87 [8.9%] vs. 72 [7.6%]; p ¼ 0.36), no reﬂow
(4 [0.4%] vs. 1 [0.1%]; p ¼ 0.38), or abrupt closure (33
[3.3%] vs. 34 [3.5%]; p ¼ 0.80) between ticagrelor and
clopidogrel treatment groups (Table 9).
Discussion
Enhanced platelet inhibition with intravenous glycoprotein
IIb/IIIa inhibitors has been associated with improved
angiographic outcomes before and after PCI (6–8). There-
fore, it was hypothesized that ticagrelor, compared with
clopidogrel, might improve angiographic outcomes because
of its more potent and predictable platelet inhibition.
Table 8. Secondary Pre-PCI Angiographic Variables
n Overall Ticagrelor Clopidogrel p Value
Thrombus grade 2,057
0 ¼ no thrombus 531 (25.8) 252 (24.1) 279 (27.6) 0.3571
1 ¼ hazy-possible thrombus present 371 (18.0) 179 (17.1) 192 (19.0)
2 ¼ thrombus present-small size 50 (2.4) 28 (2.7) 22 (2.2)
3 ¼ thrombus present-moderate size 144 (7.0) 76 (7.3) 68 (6.7)
4 ¼ thrombus present-large size 118 (5.7) 61 (5.8) 57 (5.6)
5 ¼ recent total occlusion 837 (40.7) 445 (42.6) 392 (38.7)
6 ¼ chronic total occlusion 6 (0.3) 4 (0.4) 2 (0.2)
Lesion calciﬁed 2,052 123 (6.0) 65 (6.2) 58 (5.7) 0.6433
Diffuse lesion 1,215 66 (5.4) 43 (7.2) 23 (3.7) 0.0077
Bifurcation lesion 2,056 225 (10.9) 119 (11.4) 106 (10.5) 0.5252
Ostial lesion 2,055 99 (4.8) 52 (5.0) 47 (4.6) 0.7577
Pulsatile ﬂow 1,182 457 (38.7) 215 (37.0) 242 (40.3) 0.2568
Deceleration 1,183 514 (43.5) 240 (41.2) 274 (45.6) 0.1425
Collaterals 1,965
None 1,282 (65.2) 650 (64.9) 632 (65.6) 0.3648
Partial 286 (14.5) 146 (14.6) 140 (14.5)
Complete 388 (19.8) 203 (20.3) 185 (19.2)
Myocardial 9 (0.5) 2 (0.2) 7 (0.7)
Lesion complexity 2,055
Type A 192 (9.3) 90 (8.6) 102 (10.1) 0.0694
Type B1 1,109 (54.0) 546 (52.3) 563 (55.7)
Type B2 659 (32.1) 351 (33.6) 308 (30.5)
Type C 95 (4.6) 57 (5.5) 38 (3.8)
Values are n (%).
PCI ¼ percutaneous coronary intervention.
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680However, among patients randomized to either ticagrelor or
clopidogrel, the primary hypothesis in the PLATO angio-
graphic substudy failed with no signiﬁcant difference in
myocardial perfusion, epicardial ﬂow, PCI complications, or
other angiographic outcomes either before or after PCI. The
inclusion of patients pretreated with clopidogrel may have
minimized the ability to discern differences in angiographic
outcomes immediately following PCI that would be attrib-
utable to platelet inhibition. Interestingly, more patients in
the ticagrelor group had diffuse disease. However, this
should be interpreted with caution given the small number
of patients that had diffuse disease overall.
Adenosine induces vasodilation by interacting with A2A
adenosine receptors in the smooth muscle cells. In clinical
studies, intracoronary adenosine has been demonstrated to
improve CTFC (17,18). Despite the inhibition of cellular
adenosine reuptake and, thereby, extended half-life and
increased presence of extracellular adenosine by ticagrelor
(19), there were no signiﬁcant differences in improvement in
epicardial ﬂow or myocardial perfusion among patients
treated with ticagrelor versus clopidogrel. Ticagrelor has
previously been shown to augment adenosine-induced in-
crease in coronary blood ﬂow in volunteers without ischemia
(20). In the absence of infused adenosine, such an effectcould not be determined in PLATO patients. Absence of an
effect could be due to lack of sufﬁcient local endogenous
adenosine to inﬂuence the angiographic measurements.
Intracoronary nitrate administration has been demonstrated
to inﬂuence coronary ﬂow (21,22). In the present PLATO
angiographic substudy, details of intracoronary nitrate
administration and the potential effects of intracoronary
nitrate overriding any inﬂuence of adenosine are not known.
Moreover, in the present study, aspirin dosages and use of
glycoprotein IIb/IIIa inhibitors did not have any impact on
the primary angiographic outcome.
Prior data in healthy volunteers demonstrated that ab-
sorption of ticagrelor was rapid (median time to peak plasma
concentration [tmax] 1.3 to 2 h), as was the formation of its
main (active) metabolite, AR-C124910XX, tmax 1.5 to 3 h
(23). In the present PLATO angiography substudy, the
duration of exposure to ticagrelor was short, given that PCI
was performed 0.7 h (median) following 180 mg of tica-
grelor and shortly after presentation with ACS symptoms.
This allowed little time to affect myocardial perfusion as
measured using TMPG.
Ticagrelor achieved more rapid and greater platelet in-
hibition than high-loading-dose clopidogrel did in the
ONSET-OFFSET study (24). In another analysis from
Table 9. PCI Complications
n Overall Ticagrelor Clopidogrel p Value
Dissection grade 1,974
None 1,933 (97.9) 992 (98.4) 941 (97.4) 0.6066
A 15 (0.8) 7 (0.7) 8 (0.8)
B 16 (0.8) 6 (0.6) 10 (1.0)
C 4 (0.2) 1 (0.1) 3 (0.3)
D 2 (0.1) 1 (0.1) 1 (0.1)
E 2 (0.1) 0 (0.0) 2 (0.2)
F 2 (0.1) 1 (0.1) 1 (0.1)
Perforation 1,973
None 1,965 (99.6) 1,001 (99.4) 964 (99.8) 0.4843
Localized 4 (0.2) 3 (0.3) 1 (0.1)
Nonlocalized 4 (0.2) 3 (0.3) 1 (0.1)
Loss of side branch 1,967 107 (5.4) 63 (6.3) 44 (4.6) 0.1113
Success restoration of side branch 104 24 (23.1) 13 (21.3) 11 (25.6) 0.6424
Distal embolization 1,938 159 (8.2) 87 (8.9) 72 (7.6) 0.3631
No reﬂow 1,959 5 (0.3) 4 (0.4) 1 (0.1) 0.3750
Abrupt closure 1,968 67 (3.4) 33 (3.3) 34 (3.5) 0.8042
Type of abrupt closure 66
Transient 56 (84.9) 28 (87.5) 28 (82.4) 0.7344
Sustained 10 (15.1) 4 (12.5) 6 (17.6)
Values are n (%).
PCI ¼ percutaneous coronary intervention.
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681the ONSET-OFFSET study, maximum (peak) plasma
concentration (Cmax), time to Cmax (tmax), and area under
the plasma concentration–time curve from time 0 to 8 h
(AUC8) for ticagrelor were 733 ng/ml, 2.0 h, and 4,130 ng $
h/ml, respectively (25).
In the RESPOND (Response to Ticagrelor in Clopidogrel
Nonresponders and Responders and Effect of Switching
Therapies) study (26), ticagrelor therapy overcame the
nonresponsiveness to clopidogrel, and its antiplatelet effect
was the same in responders and nonresponders among
patients with stable coronary artery disease. In another
analysis from the RESPOND study, ticagrelor mean Cmax
and area under the curve following 2-week dosing were
comparable between clopidogrel responders (724 ng/ml and
3,983 ng $ h/ml, respectively) and nonresponders (764 ng/ml
and 3,986 ng $ h/ml, respectively). Pharmacokinetics of
ticagrelor were unaffected by prior clopidogrel dosing (25). In
the PLATO angiographic substudy consisting of unstable
patients (unstable angina, NSTE-ACS, STEMI), overall,
21.3% of patients had received clopidogrel 600 mg before
randomization and demonstrated no difference in the
angiographic outcomes between the 2 groups.
Although these data are in healthy volunteers and stable
patients, the pharmacokinetics might be different in the
setting of ACS. In a recent study by Alexopoulos et al. (27),
among patients with STEMI undergoing primary PCI
treated with ticagrelor, the pharmacodynamic (PD) effects
were slower than those reported from other studies (i.e.,ONSET-OFFSET and RESPOND) in stable patients.
The PLATO angiographic substudy consisted of patients
with STEMI, unstable angina, and NSTE-ACS. Therefore,
slower PD effects of ticagrelor and short duration of
exposure of the drug might explain the lack of difference
in the angiographic outcomes compared with those of
clopidogrel.
Given the short time interval of ticagrelor exposure in the
PLATO angiographic substudy, the ATLANTIC (A 30
Day Study to Evaluate Efﬁcacy and Safety of Pre-Hospital
vs. In-hospital Initiation of Ticagrelor Therapy in STEMI
Patients Planned for Percutaneous Coronary Intervention)
study, which is currently underway, will assess the efﬁcacy
and safety of pre-hospital versus in-hospital administration of
ticagrelor coadministered with aspirin, on restoring blood
ﬂow in occluded coronary arteries and improving myocardial
perfusion among STEMI patients undergoing primary PCI.
The ERASE MI (Early Rapid Reversal of Platelet
Thrombosis With Intravenous Elinogrel Before PCI To
Optimize Reperfusion in Acute Myocardial Infarction) pilot
trial (28), was a phase IIA, randomized, double-blind,
placebo-controlled, dose-escalation study designed to eval-
uate the safety of escalating doses (10, 20, 40, and 60 mg) of
elinogrel, a P2Y12 inhibitor administered as a single intra-
venous bolus before the start of the diagnostic angiogram
preceding primary PCI. In ERASE MI, using an intrave-
nous P2Y12 inhibitor prior to primary PCI compared with
placebo, there were no differences in CTFC (28).
Kunadian et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3
PLATO Angiographic Substudy J U L Y 2 0 1 3 : 6 7 1 – 8 3
682The PD differences between glycoprotein IIb/IIIa
inhibitors and P2Y12 inhibitors might explain the lack of
signiﬁcant impact of ticagrelor on TMPG (29). An oral
P2Y12 agent such as ticagrelor has a slower and weaker PD
effect and blocks a single platelet receptor when compared
with a glycoprotein IIb/IIIa inhibitor that profoundly blocks
the platelet response to all agonists. This is important
because the hypothesis for the PLATO angiographic sub-
study was based on the observations made from studies using
glycoprotein IIb/IIIa inhibitors. It has been suggested that
small molecule glycoprotein IIb/IIIa can replace ﬁbrinogen
in platelet aggregates and can cause disaggregation, partic-
ularly in microvasculature (29). In the present study, the
primary endpoint of TMPG 3 was not achieved in the
presence of P2Y12 receptor inhibition with ticagrelor versus
clopidogrel among those that did and did not receive
a glycoprotein IIb/IIIa inhibitor.
Study limitations. The angiographic substudy is limited by
its small sample size. Not all angiographic parameters were
evaluable in all angiograms. The timing of PCI procedures
following oral study drug administration was short and
varied among patients. An imaging technique performed
several days after rather than immediately following PCI
(e.g., cardiac magnetic resonance imaging) might have
detected the target and more subtle changes, such as
hyperenhancement, that may have ensued later following the
procedure rather than at the completion of the procedure.
Conclusions
Neither coronary ﬂow nor myocardial perfusion evaluated
on coronary angiograms performed before or after PCI
procedures within a few hours after start of oral antiplatelet
treatment in the setting of AC, demonstrated a difference
with ticagrelor versus clopidogrel.
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